If you have been reading about secretagogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
=== 2022: In the Court of the Crimson King documentary; end of band activity === Following the band's 2021 tour dates, King Crimson ceased activity without expressly announcing a breakup. Fripp cited practical reasons for concluding the band's touring career, such as the old age of several of the members and the rising cost of services during the COVID-19 pandemic. On 9 February 2022, founding King Crimson member Ian McDonald died of cancer. In March 2022, the documentary film In the Court of the Crimson King was premiered at the 2022 SXSW Film Festival. Directed by Toby Amies and filmed between 2019 and 2021, it covered live and backstage activity by the then-current band but also featured a historical overview plus contributions from Crimson alumni Ian McDonald, Michael Giles, Bill Bruford, Adrian Belew and Trey Gunn (as well as prolonged interview footage with the late Bill Rieflin). Amies described the film's development as follows: "What began as a traditional documentary about the legendary band King Crimson as it turned fifty, mutated into an exploration of time, death, family, and the transcendent power of music to change lives; but with jokes." As of 2022, no King Crimson activity was planned for the future, excepting ongoing archive/curatorial matters. Levin said in a late 2022 interview that "the sense I got from Robert [Fripp] was that it's over.
As clean energy from wind, solar or hydro storage replaces pollution from gas, oil and coal, EU law has standards for generation and distribution networks. First, in generation, the Renewable Energy Directive 2018 still enables biomass and biofuel to count toward "renewable" energy statistics based on the argument that trees or plants absorb greenhouse gases when they grow, even though biomass burning (usually in ex-coal plants) releases more greenhouse gases than coal, biomass transport is not clean, forests take decades to replenish, and smoke damages human health. Second, the EU does not yet have a feed-in tariff system, requiring energy grids and retailers to pay a fair price to households or businesses with solar or wind generation, however in PreussenElektra AG v Schleswag AG the Court of Justice held that member states could fix any price they chose, so that energy companies would have to reimburse producers for the energy they received. A company now owned by E.ON claimed the feed-in tariff was state aid under TFEU article 107, and should have to pass rules for exemption, as a way to hinder renewable energy funding. The Court rejected this, because although the policy might have 'negative repercussions' for big energy companies it 'cannot be regarded' as giving to small producers 'a particular advantage at the expense of the state'.
== Theca interna == Theca interna cells express receptors for luteinizing hormone (LH) to produce androstenedione (an androgen), which via a few steps, gives the granulosa cells the precursor for estrogen manufacturing. After rupture of the mature ovarian follicle, the theca interna cells differentiate into the theca lutein cells of the corpus luteum, which continue to secrete androgens.
Exertional rhabdomyolysis (ER) is the breakdown of muscle from extreme physical exertion. It is one of many types of rhabdomyolysis that can occur, and because of this, the exact prevalence and incidence are unclear.
Extracting helium from air is not economical. For large-scale use, helium is extracted by fractional distillation from natural gas, which can contain as much as 7% helium. Since helium has a lower boiling point than any other element, low temperatures and high pressure are used to liquefy nearly all the other gases (mostly nitrogen and methane). The resulting crude helium gas is purified by successive exposures to lowering temperatures, in which almost all of the remaining nitrogen and other gases are precipitated out of the gaseous mixture. Activated charcoal is used as a final purification step, usually resulting in 99.995% pure Grade-A helium. The principal impurity in Grade-A helium is neon. In a final production step, most of the helium that is produced is liquefied via a cryogenic process. This is necessary for applications requiring liquid helium and also allows helium suppliers to reduce the cost of long-distance transportation, as the largest liquid helium containers have more than five times the capacity of the largest gaseous helium tube trailers. In 2008, approximately 169 million standard cubic meters (SCM) (6.0 × 109 cubic feet) of helium were extracted from natural gas or withdrawn from helium reserves, with approximately 78% from the United States, 10% from Algeria, and most of the remainder from Russia, Poland, and Qatar. By 2013, increases in helium production in Qatar (under the company Qatargas managed by Air Liquide) had increased Qatar's fraction of world helium production to 25%, making it the second largest exporter after the United States.
Sources: en.wikipedia.org
. The azide side chains of L-Aha allow highly specific and efficient site-specific conjugation to a lot different of functional molecules via Staudinger ligation with phosphine reagents, and Copper (I)-catalysed azide-alkyne cycloaddition (CuAAC) or Strain promoted azide-alkyne cycloaddition (SPAAC) in click reactions.
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system. In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO. Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. As of 2016, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides". The drug was rejected for FDA approval in 2017 and 2020.
== Incident and aftermath == RaDonda Vaught began work as a nurse at Vanderbilt University Medical Center in December 2015. On December 24, 2017, 75-year-old Charlene Murphey was admitted to the hospital for a subdural hematoma. Two days later, Vaught, a registered nurse, was instructed to administer Versed (midazolam, a sedating drug) to Murphey, but instead administered vecuronium (a paralyzing drug). Murphey was to be given Versed prior to an MRI scan. Vaught initially tried to withdraw Versed from an automated dispensing cabinet which was designed to communicate with the hospital's Medication Administration Record (MAR). Though an order for the intended medication (Versed) was present in Murphey's MAR, Vaught "couldn't find [it] in Murphey's profile" in the dispensing cabinet after typing "VE" into its search function without realizing she should have been looking for its generic name, midazolam. Vaught then triggered an override that unlocked a much larger swath of medications and then searched for "VE" again, and selected the first medication in the list (vecuronium). Vaught claimed that using overrides was a common and daily occurrence; other witnesses similarly testified that technical issues and delays at medication cabinets were common, and that "nurses could use overrides to overcome those delays." Vaught looked at the back of the vial and saw that it needed to be reconstituted, but did not look at the front of the vial to verify that it was, indeed, Versed. Vaught proceeded to reconstitute the vial, went to the imaging unit, and administered a dose to Murphey.
==== Media, social, internal and foreign affairs ==== Defense, National Security and Emergency Committee Diplomatic and Consular Affairs Committee Public Freedoms and Human Rights Committee Media Committee Social Affairs and Labor Committee Youth and Sports Committee Family and Women Committee Endowments, Religious Affairs and Fatwa Committee
Sources: en.wikipedia.org
=== Small RNA molecules regulate gene expression by post-transcriptional gene silencing === Another previously unknown mechanism by which RNA molecules are involved in genetic regulation was discovered in the 1990s. Small RNA molecules termed microRNA (miRNA) and small interfering RNA (siRNA) are abundant in eukaryotic cells and exert post-transcriptional control over mRNA expression. They function by binding to specific sites within the mRNA and inducing cleavage of the mRNA via a specific silencing-associated RNA degradation pathway.
Fraser fir is endemic to the highest parts of the southern Appalachian Mountains, where along with red spruce it forms a fragile ecosystem known as the Southern Appalachian spruce–fir forest. Fraser fir rarely occurs below 5,500 ft (1,700 m), and becomes the dominant tree type at 6,200 ft (1,900 m). By contrast, balsam fir is found from near sea level to the tree line in the northern Appalachians, but ranges only as far south as Virginia and West Virginia in the central Appalachians, where it is usually confined above 3,900 ft (1,200 m) asl, except in cold valleys. Curiously, it is associated with oaks in Virginia. The balsam fir of Virginia and West Virginia is thought by some to be a natural hybrid between the more northern variety and Fraser fir. While red spruce is common in both upland and bog habitats, balsam fir, as well as black spruce and tamarack, are more characteristic of the latter. However, balsam fir also does well in soils with a pH as high as 6. Eastern or Canada hemlock (Tsuga canadensis) is another important evergreen needle-leaf conifer that grows along the Appalachian chain from north to south but is confined to lower elevations than red spruce and the firs. It generally occupies richer and less acidic soils than the spruce and firs and is characteristic of deep, shaded and moist mountain valleys and coves. It is subject to the hemlock woolly adelgid (Adelges tsugae), an introduced insect, that is rapidly extirpating it as a forest tree. Less abundant, and restricted to the southern Appalachians, is Carolina hemlock (Tsuga caroliniana).
== Volkswagens == Largest gathering of Volkswagens: Thailand broke the Guinness World Record for the largest congregation of Volkswagens. That honour was held previously by Brazil. A total of 490 Volkswagens gathered at the First Army Area to break Brazil's previous record of 460 Volkswagens.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.